close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Amneal Pharmaceuticals LLC

News headline image
Amneal Receives U.S. FDA Approval for Iohexol Injection
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal Reports Third Quarter 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal to Report Third Quarter 2025 Results on October 30, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal Reports Second Quarter 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal to Report Second Quarter 2025 Results on August 5, 2025
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal to Participate at Upcoming Investor Conferences in June
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
News headline image
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Tickers AMRX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today